cassava
sciences
announces
final
results
phase
clinical
study
sumifilam
patients
alzheimer
disease
nasdaq
sava
alzheimer
patients
drug
groups
showed
statistically
significant
improvements
biomarkers
disease
compared
placebo
group
p
alzheimer
patients
drug
groups
showed
improved
cognition
compared
placebo
group
effect
size
sumifilam
safe
company
host
conference
call
today
et
conference
call
include
md
principal
investigator
phase
study
sumifilam
ongoing
study
sumifilam
patients
alzheimer
disease
austin
texas
globe
newswire
cassava
sciences
nasdaq
sava
today
announced
final
results
phase
study
lead
drug
candidate
sumifilam
alzheimer
disease
clinical
study
funded
national
institutes
health
nih
sumifilam
significantly
improved
entire
panel
validated
biomarkers
disease
patients
alzheimer
disease
ability
improve
multiple
biomarkers
distinct
biological
pathways
one
drug
never
shown
patients
alzheimer
disease
study
results
expected
published
publication
sumifilam
first
new
class
drug
compounds
bind
protein
called
filamin
molecules
new
alzheimer
research
may
represent
important
advance
data
replicated
larger
studies
said
jeffrey
cummings
founding
director
cleveland
clinic
lou
ruvo
center
brain
health
chambers
professor
brain
science
university
nevada
las
vegas
pleased
see
early
evidence
effects
patients
investigational
drug
data
appear
represent
step
forward
toward
urgently
needed
treatments
alzheimer
addition
alzheimer
patients
treated
sumifilam
showed
directional
improvements
tests
remembering
new
information
versus
patients
placebo
improvements
cognition
correlated
strongly
decreases
biomarker
elevated
leads
tangles
brain
sumifilam
decreased
brain
levels
versus
placebo
study
alzheimer
patients
treated
mg
mg
sumifilam
days
showed
statistically
significant
p
improvements
biomarkers
disease
pathology
neurodegeneration
neuroinflammation
versus
alzheimer
patients
took
placebo
addition
alzheimer
patients
treated
sumifilam
showed
directional
improvements
validated
tests
episodic
memory
spatial
working
memory
versus
patients
placebo
effect
sizes
cognitive
improvements
correlated
strongly
decreases
study
achieved
response
rate
defined
proportion
study
participants
taking
sumifilam
showed
improvements
biomarkers
clinical
data
suggest
sumifilam
may
slowing
disease
progression
alzheimer
patients
said
nadav
friedmann
phd
md
chief
medical
officer
cassava
sciences
exciting
possibility
need
evaluated
future
collaborations
patients
physicians
advisors
drugs
help
ease
decline
really
nothing
treat
people
alzheimer
said
remi
barbier
chairman
president
ceo
cassava
sciences
improvement
multiple
biomarkers
clinical
study
first
offers
hope
sumifilam
potential
become
transformative
treatment
people
alzheimer
phase
study
design
phase
randomized
clinical
study
sumifilam
formerly
patients
alzheimer
disease
age
randomized
mg
mg
oral
sumifilam
matching
placebo
treatment
administered
twice
daily
days
nine
study
sites
enrolled
patients
clinical
diagnosis
alzheimer
disease
confirmed
state
examination
mmse
csf
aβ
ratio
safety
assessed
ecgs
clinical
labs
adverse
event
monitoring
physical
examinations
phase
study
results
study
drug
safe
patient
discontinuations
study
used
biomarkers
measure
drug
effects
biomarkers
objective
biological
endpoints
used
track
progression
alzheimer
disease
molecular
aberrations
brain
reflected
biomarkers
found
cerebrospinal
fluid
csf
fluid
surrounds
brain
key
objective
study
measure
changes
levels
csf
biomarkers
study
participants
days
treatment
percent
change
baseline
key
biomarker
results
include
following
versus
placebo
core
markers
alzheimer
pathology
total
tau
phosphorylated
tau
amyloid
aβ
alzheimer
tau
levels
elevated
aβ
low
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
aβ
increased
p
patients
mg
drug
group
aβ
increased
p
patients
mg
drug
group
alzheimer
tau
levels
elevated
aβ
low
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
aβ
increased
p
patients
mg
drug
group
aβ
increased
p
patients
mg
drug
group
elevated
csf
levels
two
proteins
neurogranin
ng
neurofilament
light
chain
nfl
indicate
neurodegeneration
ng
decreased
p
patients
mg
drug
group
ng
decreased
p
patients
mg
drug
group
nfl
decreased
p
patients
mg
drug
group
nfl
decreased
p
patients
mg
drug
group
ng
decreased
p
patients
mg
drug
group
ng
decreased
p
patients
mg
drug
group
nfl
decreased
p
patients
mg
drug
group
nfl
decreased
p
patients
mg
drug
group
proinflammatory
interleukin
produced
response
tissue
stress
injury
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
elevated
levels
neuroinflammatory
marker
indicate
microglial
activation
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
neuroinflammation
biomarker
commanded
substantial
recent
attention
researchers
role
alzheimer
disease
frontotemporal
dementia
decreased
p
patients
mg
drug
group
decreased
p
patients
mg
drug
group
objective
study
measure
drug
effects
cognition
patients
tested
baseline
day
changes
episodic
memory
spatial
working
memory
assessed
cantab
validated
battery
tests
cantab
designed
measure
cognitive
skills
regardless
subject
language
skills
speed
gender
education
directional
trends
observed
due
limitations
around
study
size
key
cognition
results
include
alzheimer
patients
drug
groups
showed
directional
improvements
tests
episodic
memory
spatial
memory
days
treatment
versus
patients
placebo
effect
sizes
versus
placebo
episodic
memory
improved
lower
score
better
alzheimer
patients
mg
drug
group
versus
patients
placebo
episodic
memory
improved
lower
score
better
alzheimer
patients
mg
drug
group
versus
patients
placebo
spatial
memory
improved
lower
score
better
alzheimer
patients
mg
drug
group
versus
patients
placebo
spatial
memory
improved
lower
score
better
alzheimer
patients
mg
drug
group
versus
patients
placebo
improvements
cognition
correlated
strongly
statistical
decreases
csf
biomarker
elevated
leads
tangles
brain
sumifilam
decreased
brain
levels
versus
placebo
study
methods
cerebrospinal
fluid
csf
bioanalysis
csf
drawn
study
participants
lumbar
puncture
outpatient
procedure
used
remove
small
sample
csf
lower
spine
study
participants
underwent
two
csf
draws
treatment
started
continuous
days
treatment
csf
samples
sent
outside
labs
bioanalysis
bioanalysis
refers
set
laboratory
tests
detect
measure
small
amounts
pg
ml
biomarkers
csf
bioanalyses
conducted
blinded
conditions
eliminate
possibility
bias
academic
lab
generated
final
results
validity
final
results
evidenced
robust
correlations
average
biomarker
movements
days
dataset
placebo
samples
small
changes
biomarkers
placebo
group
expected
previously
disclosed
initial
bioanalysis
different
lab
showed
highly
anomalous
data
huge
swings
directions
levels
biomarkers
well
biomarkers
moving
opposite
directions
patients
group
took
placebo
days
validity
question
initial
bioanalysis
serves
useful
purpose
phase
study
conclusions
small
study
sumifilam
showed
promising
treatment
effects
patients
alzheimer
disease
study
sumifilam
treatment
days
improved
entire
panel
validated
biomarkers
alzheimer
disease
decreased
measurements
neuroinflammation
showed
responder
rate
appears
safe
appears
benefit
cognition
importantly
data
consistent
prior
clinical
preclinical
results
drug
mechanism
action
years
basic
research
ongoing
open
label
study
cassava
sciences
conducting
ongoing
extension
study
sumifilam
mg
months
study
target
enrollment
approximately
patients
alzheimer
disease
including
patients
prior
studies
sumifilam
study
currently
enrolled
alzheimer
disease
alzheimer
disease
progressive
brain
disorder
destroys
memory
thinking
skills
currently
drug
therapies
halt
alzheimer
disease
much
less
reverse
course
alone
approximately
million
people
currently
living
alzheimer
disease
approximately
people
age
older
developed
alzheimer
number
people
living
alzheimer
disease
expected
grow
dramatically
years
ahead
resulting
growing
social
economic
sumifilam
sumifilam
proprietary
small
molecule
oral
drug
restores
normal
shape
function
altered
filamin
flna
scaffolding
protein
brain
altered
flna
brain
disrupts
normal
function
neurons
leading
alzheimer
pathology
neurodegeneration
neuroinflammation
underlying
science
sumifilam
published
journals
including
journal
neuroscience
neurobiology
aging
journal
biological
chemistry
neuroimmunology
neuroinflammation
journal
prevention
alzheimer
disease
company
also
developing
investigational
diagnostic
called
savadx
detect
alzheimer
disease
simple
blood
test
sumifilam
savadx
developed
product
candidates
substantially
funded
research
grant
awards
national
institutes
health
cassava
sciences
owns
worldwide
development
commercial
rights
research
programs
alzheimer
disease
related
technologies
without
royalty
obligations
third
party
patent
protection
area
currently
runs
beyond
plus
extensions
includes
seven
issued
patents
related
patent
filings
applications
cassava
sciences
cassava
sciences
mission
discover
develop
innovations
chronic
neurodegenerative
conditions
past
years
cassava
sciences
combined
technology
new
insights
neurobiology
develop
novel
solutions
alzheimer
disease
information
please
visit
https
information
contact
eric
schoen
chief
financial
officer
cassava
sciences
eschoen
cassava
sciences
phase
study
sumifilam
alzheimer
disease
funded
clinical
research
grant
national
institutes
health
nih
nia
content
press
release
solely
responsibility
cassava
sciences
necessarily
represent
official
views
nih
nia
cautionary
note
regarding
statements
press
release
contains
statements
purposes
private
securities
litigation
reform
act
act
cassava
sciences
claims
protection
safe
harbor
statements
contained
act
statements
statements
historical
fact
contained
press
release
including
limited
statements
regarding
status
current
future
clinical
studies
sumifilam
interpretation
results
phase
clinical
studies
including
cognition
data
plans
publish
results
journal
potential
health
benefits
changes
levels
biomarkers
verbal
commentaries
made
cassava
sciences
employees
scientific
advisors
potential
benefits
company
product
candidates
alzheimer
disease
statements
statements
based
largely
company
current
expectations
projections
future
events
statements
speak
date
press
release
subject
number
risks
uncertainties
assumptions
including
limited
risks
relating
ability
conduct
complete
clinical
studies
expected
timelines
demonstrate
specificity
safety
efficacy
potential
health
benefits
product
candidates
severity
duration
health
care
precautions
given
pandemic
unanticipated
impacts
pandemic
business
operations
including
described
section
entitled
risk
factors
cassava
sciences
annual
report
form
year
ended
december
future
reports
filed
sec
light
risks
uncertainties
assumptions
statements
events
discussed
press
release
inherently
uncertain
may
occur
actual
results
could
differ
materially
adversely
anticipated
implied
statements
accordingly
rely
upon
statements
predictions
future
events
except
required
law
company
disclaims
intention
responsibility
updating
revising
statements
contained
press
release
information
regarding
risks
related
business
investors
consult
filings
sec
available
sec
website
